Syrian Rue: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews

Overview

Syrian rue (Peganum harmala) is a plant that is native to the western United States, Asia, Africa, and Europe. The seeds of the plant can cause hallucinations.

Syrian rue seeds contain chemicals called beta-carbolines. These chemicals cause many different effects in the body, such as stimulant effects and those that are similar to certain medicines used to treat Alzheimer disease.

People use Syrian rue for osteoarthritis, cancer, menstrual pain, and many other conditions, but there is no good scientific evidence to support these uses. It is also unsafe.

Uses & Effectiveness

We currently have no information for Syrian Rue overview.

Side Effects

When taken by mouth: Syrian rue is possibly unsafe in low doses. Taking 3-4 grams of Syrian rue seeds can cause hallucinations and stimulant effects. Syrian rue is likely unsafe in higher doses. Serious side effects affecting the nervous system, heart, liver, and kidneys, as well as death, have been reported.

When applied to the skin: Syrian rue is possibly safe when diluted in olive oil.

Special Precautions and Warnings

Pregnancy and breast-feeding: Syrian rue is likely unsafe when taken by mouth during pregnancy or breast-feeding. Syrian rue can induce labor. It may also cause an abortion. Avoid use.

Heart conditions: Syrian rue contains the chemicals harmaline and harmine. These might cause complications in people who have a slow heart rate or heart disease.

Blockage in the stomach: Syrian rue contains the chemicals harmaline and harmine. These chemicals might cause complications in people who have a blockage in the stomach.

Liver disease: Liver damage has occurred in people who have taken Syrian rue. People with liver diseases, including hepatitis, should avoid taking Syrian rue.

Stomach ulcers: Syrian rue contains the chemicals harmaline and harmine. These chemicals might cause complications in people who have stomach ulcers.

Lung conditions: Syrian rue contains the chemicals harmaline and harmine. These chemicals might cause complications in people who have lung conditions, including asthma and chronic obstructive pulmonary disease (COPD).

Seizures: Syrian rue contains the chemicals harmaline and harmine. These chemicals might cause complications in people who have seizures.

Surgery: Syrian rue can affect levels of serotonin in the brain. This might interfere with surgical procedures. Discontinue Syrian rue use at least 2 weeks before a planned surgery.

Blockage in the urinary tract: Syrian rue contains the chemicals harmaline and harmine. These chemicals might cause complications in people who have a blockage in the urinary tract.

Interactions

Moderate Interaction

Be cautious with this combination

Serotonergic drugs interacts with Syrian Rue
Syrian rue might increase a brain chemical called serotonin. Some medications also have this effect. Taking Syrian rue along with these medications might increase serotonin too much. This might cause serious side effects including heart problems, seizures, and vomiting.
Drying medications (Anticholinergic drugs) interacts with Syrian Rue
Syrian rue can increase a chemical in the body called acetylcholine. Acetylcholine plays a big part in many important body functions. Some medications, called anticholinergic drugs, block the effects of acetylcholine in the body. Taking Syrian rue might decrease the effects of anticholinergic drugs.
Caffeine interacts with Syrian Rue
Syrian rue contains a chemical called harmaline. Taking caffeine with harmaline might increase the risk for tremors.
Various medications used for glaucoma, Alzheimer disease, and other conditions (Cholinergic drugs) interacts with Syrian Rue
Syrian rue can increase a chemical in the body called acetylcholine. Some medications that are used for glaucoma, Alzheimer disease, and other conditions, also increase acetylcholine levels. Taking Syrian rue with these medications might increase the chance of side effects.
Medications changed by the liver (Cytochrome P450 2D6 (CYP2D6) substrates) interacts with Syrian Rue
Some medications are changed and broken down by the liver. Syrian rue might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
Medications changed by the liver (Cytochrome P450 3A4 (CYP3A4) substrates) interacts with Syrian Rue
Some medications are changed and broken down by the liver. Syrian rue might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
Medications used for Parkinson disease (Dopamine agonists) interacts with Syrian Rue
Syrian rue contains chemicals that can affect the brain. These chemicals affect the brain similarly to some medications used for Parkinson disease. Taking Syrian rue with these medications might increase their effects and side effects.
Medications that can harm the liver (Hepatotoxic drugs) interacts with Syrian Rue
Syrian rue might harm the liver. Some medications can also harm the liver. Taking Syrian rue along with a medication that can harm the liver might increase the risk of liver damage.

Dosing

There isn't enough reliable information to know what an appropriate dose of Syrian rue might be. Keep in mind that natural products are not always necessarily safe and dosages can be important. Be sure to follow relevant directions on product labels and consult a healthcare professional before using.

View References

REFERENCES:

Yuruktumen, A., Karaduman, S., Bengi, F., and Fowler, J. Syrian rue tea: a recipe for disaster. Clin Toxicol (Phila) 2008;46(8):749-752.

Kawanishi, K., Hashimoto, Y., Fujiwara, M., Kataoka, Y., and Ueki, S. Pharmacological characteristics of abnormal behavior induced by harmine with special reference to tremor in mice. J Pharmacobiodyn 1981;4(7):520-527.

Morcuende, S., Trigo, J. A., Delgado-Garcia, J. M., and Gruart, A. Harmaline induces different motor effects on facial vs. skeletal-motor systems in alert cats. Neurotox Res 2001;3(6):527-535.

Deecher, D. C., Teitler, M., Soderlund, D. M., Bornmann, W. G., Kuehne, M. E., and Glick, S. D. Mechanisms of action of ibogaine and harmaline congeners based on radioligand binding studies. Brain Res 1992;571(2):242-247.

Ahmad, A., Khan, K. A., Sultana, S., Siddiqui, B. S., Begum, S., Faizi, S., and Siddiqui, S. Study of the in vitro antimicrobial activity of harmine, harmaline and their derivatives. J Ethnopharmacol 1992;35(3):289-294.

Arshad, N., Zitterl-Eglseer, K., Hasnain, S., and Hess, M. Effect of Peganum harmala or its beta-carboline alkaloids on certain antibiotic resistant strains of bacteria and protozoa from poultry. Phytother Res 2008;22(11):1533-1538.

Arshad, N., Neubauer, C., Hasnain, S., and Hess, M. Peganum harmala can minimize Escherichia coli infection in poultry, but long-term feeding may induce side effects. Poult Sci 2008;87(2):240-249.

Gaviraj, E. N, Babu, G. R., and Murthy, U. D. Antibacterial activity guided isolation of harmine from Peganum harmala seeds by bioautography. Indian Drugs 1998;35:471-474.

Lamchouri, F., Settaf, A., Cherrah, Y., Zemzami, M., Lyoussi, B., Zaid, A., Atif, N., and Hassar, M. Antitumour principles from Peganum harmala seeds. Therapie 1999;54(6):753-758.

Nenaah, G. Antibacterial and antifungal activities of (beta)-carboline alkaloids of Peganum harmala (L) seeds and their combination effects. Fitoterapia 2010;81(7):779-782.

Pinner, E., Padan, E., and Schuldiner, S. Amiloride and harmaline are potent inhibitors of NhaB, a Na+/H+ antiporter from Escherichia coli. FEBS Lett 1995;365(1):18-22.

Fan, B., Liang, J., Men, J., Gao, F., Li, G., Zhao, S., Hu, T., Dang, P., and Zhang, L. Effect of total alkaloid of Peganum harmala L. in the treatment of experimental haemosporidian infections in cattle. Trop Anim Health Prod 1997;29(4 Suppl):77S-83S.

Edziri, H., Masouri, M., Mahjoub, M. A., Patrich, G., Matieu, M., Ammar, S., Ali, S. M., Laurent, G., Zine, M., and Aouni, M. Antibacterial, antiviral and antioxidant activities of aerial part extracts of Peganum harmala L. grown in Tunisia. Toxicol Environ Chem 2010;92(7):1283-1292.

Derakhshanfar, A. and Mirzaei, M. Effect of Peganum harmala (wild rue) extract on experimental ovine malignant theileriosis: pathological and parasitological findings. Onderstepoort J Vet Res 2008;75(1):67-72.

Di, Giorgio C., Delmas, F., Ollivier, E., Elias, R., Balansard, G., and Timon-David, P. In vitro activity of the beta-carboline alkaloids harmane, harmine, and harmaline toward parasites of the species Leishmania infantum. Exp Parasitol 2004;106(3-4):67-74.

Hu, T., Fan, B., Liang, J., Zhao, S., Dang, P., Gao, F., and Dong, M. Observations on the treatment of natural haemosporidia infections by total alkaloid of Peganum harmala L. in cattle. Trop Anim Health Prod 1997;29(4 Suppl):72S-76S.

Lala, S., Pramanick, S., Mukhopadhyay, S., Bandyopadhyay, S., and Basu, M. K. Harmine: evaluation of its antileishmanial properties in various vesicular delivery systems. J Drug Target 2004;12(3):165-175.

Cao, R., Peng, W., Chen, H., Ma, Y., Liu, X., Hou, X., Guan, H., and Xu, A. DNA binding properties of 9-substituted harmine derivatives. Biochem Biophys Res Commun 2005;338(3):1557-1563.

Chen, Q., Chao, R., Chen, H., Hou, X., Yan, H., Zhou, S., Peng, W., and Xu, A. Antitumor and neurotoxic effects of novel harmine derivatives and structure-activity relationship analysis. Int J Cancer 2005;114(5):675-682.

Hamsa, T. P. and Kuttan, G. Harmine activates intrinsic and extrinsic pathways of apoptosis in B16F-10 melanoma. Chin Med 2011;6(1):11.

Hamsa, T. and Kuttan, G. Studies on anti-metastatic and anti-invasive effects of harmine using highly metastatic murine B16F-10 melanoma cells. J Environ Pathol Toxicol Oncol 2011;30(2):123-137.

Jimenez, J., Riveron-Negrete, L., Abdullaev, F., Espinosa-Aguirre, J., and Rodriguez-Arnaiz, R. Cytotoxicity of the beta-carboline alkaloids harmine and harmaline in human cell assays in vitro. Exp Toxicol Pathol 2008;60(4-5):381-389.

Jin, Y. J. [Effects of harmaline and fluorouracil (5-FU) on human retinoblastoma cell line SO-Rb 50]. Zhonghua Yan Ke Za Zhi 1990;26(5):286-288.

Lamchouri, F., Settaf, A., Cherrah, Y., Hassar, M., Zemzami, M., Atif, N., Nadori, E. B., Zaid, A., and Lyoussi, B. In vitro cell-toxicity of Peganum harmala alkaloids on cancerous cell-lines. Fitoterapia 2000;71(1):50-54.

Ma, Y. and Wink, M. The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells. Phytother Res 2010;24(1):146-149.

Sobhani, A. M., Ebrahimi, S. A., and Mahmoudian, M. An in vitro evaluation of human DNA topoisomerase I inhibition by Peganum harmala L. seeds extract and its beta-carboline alkaloids. J Pharm Pharm Sci 2002;5(1):19-23.

Song, Z. Y., Liu, J. R., Lu, X. L., and Wang, L. J. [Harmine induces apoptosis in human SGC-7901 cells]. Zhong Yao Cai 2006;29(6):571-573.

Zaker, F., Oody, A., and Arjmand, A. A study on the antitumoral and differentiation effects of peganum harmala derivatives in combination with ATRA on leukaemic cells. Arch Pharm Res 2007;30(7):844-849.

Fortunato, J. J., Reus, G. Z., Kirsch, T. R., Stringari, R. B., Stertz, L., Kapczinski, F., Pinto, J. P., Hallak, J. E., Zuardi, A. W., Crippa, J. A., and Quevedo, J. Acute harmine administration induces antidepressive-like effects and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 2009;33(8):1425-1430.

Fortunato, J. J., Reus, G. Z., Kirsch, T. R., Stringari, R. B., Fries, G. R., Kapczinski, F., Hallak, J. E., Zuardi, A. W., Crippa, J. A., and Quevedo, J. Effects of beta-carboline harmine on behavioral and physiological parameters observed in the chronic mild stress model: further evidence of antidepressant properties. Brain Res Bull 2010;81(4-5):491-496.

Fortunato, J. J., Reus, G. Z., Kirsch, T. R., Stringari, R. B., Fries, G. R., Kapczinski, F., Hallak, J. E., Zuardi, A. W., Crippa, J. A., and Quevedo, J. Chronic administration of harmine elicits antidepressant-like effects and increases BDNF levels in rat hippocampus. J Neural Transm 2010;117(10):1131-1137.

Herraiz, T., Gonzalez, D., Ancin-Azpilicueta, C., Aran, V. J., and Guillen, H. beta-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO). Food Chem Toxicol 2010;48(3):839-845.

Seifert, A., Allan, L. A., and Clarke, P. R. DYRK1A phosphorylates caspase 9 at an inhibitory site and is potently inhibited in human cells by harmine. FEBS J 2008;275(24):6268-6280.

Farouk, L., Laroubi, A., Aboufatima, R., Benharref, A., and Chait, A. Evaluation of the analgesic effect of alkaloid extract of Peganum harmala L.: possible mechanisms involved. J.Ethnopharmacol 2008;115(3):449-454.

Mirzaei, M. Treatment of natural tropical theileriosis with the extract of the plant Peganum harmala. Korean J Parasitol 2007;45(4):267-271.

Mirzaiedehaghi, M. Treatment of natural ovine malignant theileriosis with a chloroform extract of the plant Peganum harmala. Onderstepoort J Vet Res 2006;73(2):153-155.

Monsef, H. R., Ghobadi, A., Iranshahi, M., and Abdollahi, M. Antinociceptive effects of Peganum harmala L. alkaloid extract on mouse formalin test. J Pharm Pharm Sci 2004;7(1):65-69.

Hamsa, T. P. and Kuttan, G. Harmine inhibits tumour specific neo-vessel formation by regulating VEGF, MMP, TIMP and pro-inflammatory mediators both in vivo and in vitro. Eur J Pharmacol 2010;649(1-3):64-73.

Shahverdi, A. R., Monsef-Esfahani, H. R., Nickavar, B., Bitarafan, L., Khodaee, S., and Khoshakhlagh, N. Antimicrobial activity and main chemical composition of two smoke condensates from Peganum harmala seeds. Z Naturforsch C 2005;60(9-10):707-710.

Frison, G., Favretto, D., Zancanaro, F., Fazzin, G., and Ferrara, S. D. A case of beta-carboline alkaloid intoxication following ingestion of Peganum harmala seed extract. Forensic Sci Int 2008;179(2-3):e37-e43.

Slotkin, T. A. and DiStefano, V. Cardiovascular and respiratory effects of harmine. Proc Soc Exp Biol Med 1970;133(2):662-664.

Ben Salah N., Amamou, M., Jerbi, Z., Ben Salah F., and Yacoub, M. [A case of overdose with Peganum harmala L]. J Toxicol Clin Exp 1986;6(5):319-322.

Iurlo, M., Leone, G., Schilstrom, B., Linner, L., Nomikos, G., Hertel, P., Silvestrini, B., and Svensson, H. Effects of harmine on dopamine output and metabolism in rat striatum: role of monoamine oxidase-A inhibition. Psychopharmacology (Berl) 2001;159(1):98-104.

Harsh, M. L. and Nag, T. N. Antimicrobial principles from in vitro tissue culture of Peganum harmala. J Nat Prod 1984;47(2):365-367.

Javoy, F., Euvrard, C., Herbet, A., Bockaert, J., Enjalbert, A., Agid, Y., and Glowinski, J. Lack of involvement of dopaminergic and GABA neurones in the inhbitory effect of harmaline on the activity of striatal cholinergic neurones in the rat. Naunyn Schmiedebergs Arch Pharmacol 1977;297(3):233-239.

Fuller, R. W., Wong, C. J., and Hemrick-Luecke, S. K. MD 240928 and harmaline: opposite selectivity in antagonism of the inactivation of types A and B monoamine oxidase by pargyline in mice. Life Sci 1986;38(5):409-412.

Al-Deeb, S., Al-Moutaery, K., Arshaduddin, M., Biary, N., and Tariq, M. Effect of acute caffeine on severity of harmaline induced tremor in rats. Neurosci Lett 2002;325(3):216-218.

Shukla, V. K., Garg, S. K., and Kulkarni, S. K. Modification by clonidine of harmine-induced tremors in mice: involvement of serotoninergic system. Arch Int Pharmacodyn Ther 1986;282(1):50-57.

Zhao, T., He, Y. Q., Wang, J., Ding, K. M., Wang, C. H., and Wang, Z. T. Inhibition of human cytochrome P450 enzymes 3A4 and 2D6 by β-carboline alkaloids, harmine derivatives. Phytother Res 2011;25(11):1671-1677.

Kelly, D. M. and Naylor, R. J. Mechanisms of tremor induction by harmine. Eur J Pharmacol 1974;27(1):14-24.

Abdel-Fattah, A. F., Matsumoto, K., Murakami, Y., Adel-Khalek, Gammaz H., Mohamed, M. F., and Watanabe, H. Central serotonin level-dependent changes in body temperature following administration of tryptophan to pargyline- and harmaline-pretreated rats. Gen Pharmacol 1997;28(3):405-409.

Bergstrom, M., Westerberg, G., and Langstrom, B. 11C-harmine as a tracer for monoamine oxidase A (MAO-A): in vitro and in vivo studies. Nucl Med Biol 1997;24(4):287-293.

Gerardy, J. Effect of moclobemide on rat brain monoamine oxidase A and B: comparison with harmaline and clorgyline. Prog Neuropsychopharmacol Biol Psychiatry 1994;18(4):793-802.

Sacher, J., Houle, S., Parkes, J., Rusjan, P., Sagrati, S., Wilson, A. A., and Meyer, J. H. Monoamine oxidase A inhibitor occupancy during treatment of major depressive episodes with moclobemide or St. John's wort: an [11C]-harmine PET study. J Psychiatry Neurosci 2011;36(6):375-382.

Beitz, A. J. and Saxon, D. Harmaline-induced climbing fiber activation causes amino acid and peptide release in the rodent cerebellar cortex and a unique temporal pattern of Fos expression in the olivo-cerebellar pathway. J Neurocytol 2004;33(1):49-74.

Bernard, J. F., Buisseret-Delmas, C., and Laplante, S. Inferior olivary neurons: 3-acetylpyridine effects on glucose consumption, axonal transport, electrical activity and harmaline-induced tremor. Brain Res 1984;322(2):382-387.

Kolasiewicz, W., Kuter, K., Nowak, P., Pastuszka, A., and Ossowska, K. Lesion of the cerebellar noradrenergic innervation enhances the harmaline-induced tremor in rats. Cerebellum 2011;10(2):267-280.

Pitre, S. and Srivastava, S. K. Two New Anthraquinones from the Seeds of Peganum harmala. Planta Med 1987;53(1):106-107.

Sharaf, M., el-Ansari, M. A., Matlin, S. A., and Saleh, N. A. Four flavonoid glycosides from Peganum harmala. Phytochemistry 1997;44(3):533-536.

Ahmed, A. A. and Saleh, N. A. Peganetin, a new branched acetylated tetraglycoside of acacetin from Peganum harmala. J Nat Prod 1987;50:256-258.

Gill, R. K., Kaur, J., Mahmood, S., Nagpaul, J. P., and Mahmood, A. Harmaline interactions with yeast invertase. Indian J Biochem Biophys 1998;35(2):86-90.

Song, Y., Kesuma, D., Wang, J., Deng, Y., Duan, J., Wang, J. H., and Qi, R. Z. Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine. Biochem Biophys Res Commun 2004;317(1):128-132.

Ishida, J., Wang, H. K., Bastow, K. F., Hu, C. Q., and Lee, K. H. Antitumor agents 201. Cytotoxicity of harmine and beta-carboline analogs. Bioorg Med Chem Lett 1999;9(23):3319-3324.

Meignin, C., Hilber, P., and Caston, J. Influence of stimulation of the olivocerebellar pathway by harmaline on spatial learning in the rat. Brain Res 1999;824(2):277-283.

Welsh, J. P. Systemic harmaline blocks associative and motor learning by the actions of the inferior olive. Eur J Neurosci 1998;10(11):3307-3320.

Turker, K. S. and Miles, T. S. Harmaline disrupts acquisition of conditioned nictitating membrane responses. Brain Res Bull 1984;13(2):229-233.

Moroi, K., Takashi, K., and Kuga, T. Involvement of GABAergic systems and benzodiazepine receptors in the jumping behavior induced by harmine and apomorphine in rats. Jpn J Pharmacol 1988;47(4):367-378.

Barragan, L. A., Delhaye-Bouchaud, N., and Laget, P. Drug-induced activation of the inferior olivary nucleus in young rabbits. Differential effects of harmaline and quipazine. Neuropharmacology 1985;24(7):645-654.

Mehta, H., Saravanan, K. S., and Mohanakumar, K. P. Serotonin synthesis inhibition in olivo-cerebellar system attenuates harmaline-induced tremor in Swiss albino mice. Behav Brain Res 2003;145(1-2):31-36.

Meneguz, A., Betto, P., and Ricciarello, G. Different effects of harmine on plasma concentrations of L-dopa and on cerebral dopamine metabolism in rabbits and rats. Pharmacology 1994;48(6):360-366.

Barragan, L. A. and Delhaye-Bouchaud, N. Harmaline-induced activation of the olivo-cerebellar system in young rabbits: further evidence for a transient multiinnervation of Purkinje cells by climbing fibres. Neuropharmacology 1980;19(3):305-310.

Lutes, J., Lorden, J. F., Beales, M., and Oltmans, G. A. Tolerance to the tremorogenic effects of harmaline: evidence for altered olivo-cerebellar function. Neuropharmacology 1988;27(8):849-855.

Yamazaki, M., Tanaka, C., and Takaori, S. Significance of central noradrenergic system on harmaline induced tremor. Pharmacol Biochem Behav 1979;10(3):421-427.

Berdai MA, Labib S, Harandou M. Peganum harmala L. Intoxication in a Pregnant Woman. Case Rep Emerg Med 2014;2014:783236.

Achour S, Rhalem N, Khattabi A, et al. [Peganum harmala L. poisoning in Morocco: about 200 cases]. Therapie 2012;67(1):53-8.

Abolhassanzadeh Z, Aflaki E, Yousefi G, Mohagheghzadeh A. Randomized clinical trial of peganum oil for knee osteoarthritis. J Evid Based Complementary Altern Med. 2015;20(2):126-31.

Chabir N, Ibrahim H, Romdhane H, et al. Seeds of Peganum Harmala L. chemical analysis, antimalarial and antioxidant activities, and cytotoxicity against human breast cancer cells. Med Chem. 2014;11(1):94-101.

Liu CH, Chu WL, Liao SC, Yang CC, Lin CC. Syrian rue seeds interacted with acacia tree bark in an herbal stew resulted in N,N-dimethyltryptamine poisoning. Clin Toxicol (Phila) 2019;57(10):867-9.

Abbas MW, Hussain M, Qamar M, et al. Antioxidant and anti-inflammatory effects of Peganum harmala extracts: an in vitro and in vivo study. Molecules 2021;26(19):6084.

Ghizlane EA, Manal M, Ines HA, et al. Fatal poisoning of pregnant women by peganum harmala L.: a case reports. Ann Med Surg (Lond) 2021;68:102649.

Durmaz Çelik N, Ger Akarsu F, Ozkan S, Özdemir AÖ, Aykac Ö, Memmedova F. Herbal teas can be harmful: a case of Peganum harmala induced coma in a patient with Parkinson's disease. Neurocase 2021;27(2):117-119.

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is licensed from Therapeutic Research Center, LLC. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
Licensed from Therapeutic Research Center, LLC
Copyright © 1995-2025 by Therapeutic Research Center, LLC. All Rights Reserved.

Syrian Rue - Uses, Side Effects, and More

Overview

Uses & Effectiveness

Side Effects

Special Precautions and Warnings

Interactions

Moderate Interaction

Serotonergic drugs interacts with Syrian Rue

Drying medications (Anticholinergic drugs) interacts with Syrian Rue

Caffeine interacts with Syrian Rue

Various medications used for glaucoma, Alzheimer disease, and other conditions (Cholinergic drugs) interacts with Syrian Rue

Medications changed by the liver (Cytochrome P450 2D6 (CYP2D6) substrates) interacts with Syrian Rue

Medications changed by the liver (Cytochrome P450 3A4 (CYP3A4) substrates) interacts with Syrian Rue

Medications used for Parkinson disease (Dopamine agonists) interacts with Syrian Rue

Medications that can harm the liver (Hepatotoxic drugs) interacts with Syrian Rue

Dosing